Recent Ki‐67 consensus meeting established that Ki‐67 IHC does have clinical validity for the determination of prognosis in patients with early‐stage breast cancer and proposed several recommendations that can lead to precise analytical validity of Ki‐67 IHC determination namely careful preanalytical handling and standardized visual scoring [39]. Here, MKI67 is linked to breast carcinoma.